# Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma

> **NCT02107378** · PHASE2 · TERMINATED · sponsor: **SOTIO a.s.** · enrollment: 22 (actual)

## Conditions studied

- Epithelial Ovarian Carcinoma

## Interventions

- **BIOLOGICAL:** DCVAC/OvCa
- **DRUG:** Standard of Care (Paclitaxel or topotecan or doxorubicin)

## Key facts

- **NCT ID:** NCT02107378
- **Lead sponsor:** SOTIO a.s.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** sponsor decision
- **Last updated:** 2016-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02107378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02107378, "Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02107378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*